| This week's sponsor is Patheon, part of Thermo Fisher Scientific. | | | Quickly proving efficacy in First-in-Human clinical trials is a make-or-break milestone for small biopharms whose hopes hinge upon one or two molecules. Read how CDMOs are helping these cash-strapped companies get to clinic faster. |
Today's Rundown ASCO: Pfizer’s dacomitinib bests Iressa in NSCLC overall survival showdown ASCO: Don’t write off IDO yet, says NewLink Tricida files for $150M IPO to fund kidney disease drug approval [Sponsored] It Might Be a Bumpy Ride: Why Life Sciences Companies Should Consider Embracing the New Wave of Change In silico drug developer Nimbus collects $65M in new funding round Curt Herberts to head up business development at Senti Bio ASCO: Forty Seven announces $115M IPO alongside first-in-human CD47 data Featured Story | | | Tuesday, June 5, 2018 A phase 3 trial has linked Pfizer’s dacomitinib to better overall survival than Iressa in nonsmall cell lung cancer (NSCLC). The results suggest Pfizer’s EGFR tyrosine kinase inhibitor is more effective than its aging rival but leave ample room to doubt its ability to outcompete AstraZeneca’s Tagrisso. |
|
|
| This week's sponsor is SNBL. | | | Does Your CNS Program Need a Boost? The Shortest Distance is a Straight Line. Nose-to-Brain
Brain delivery can be a hurdle for CNS drugs targeting unmet medical needs. Our technology can deliver your drug directly to the brain. Find out how! |
Top Stories Monday, June 4, 2018 Despite a run of poor results in clinical trials, IDO inhibition is still a worthy target to explore in cancer immunotherapy, NewLink's CMO Eugene Kennedy said at ASCO. Tuesday, June 5, 2018 Tricida has filed to raise $150 million to bring a chronic kidney disease drug to market. Proceeds from the planned IPO will set Tricida up to file for FDA approval of TRC101 and start building up the 80- to 100-person sales team it wants to commercialize the drug. Monday, June 4, 2018 Changes in technology and geopolitics, coupled with U.S. tax reform and new financial accounting standards, are creating disruption in accounting and financial reporting for life sciences companies. Tuesday, June 5, 2018 Nimbus Therapeutics has reined in $65 million in new capital to fund its virtual drug discovery and development pipeline and expand into new targets in immunology, oncology and metabolic diseases. Tuesday, June 5, 2018 Curt Herberts, who spearheaded a number of deals as Sangamo Therapeutics' chief business officer, is joining Senti Bio as its new CFO and CBO. Tuesday, June 5, 2018 In the 48 hours after filing for a $115 million IPO, immuno-oncology developer Forty Seven unveiled first-in-human data for its CD47-targeting monoclonal antibody at the American Society of Clinical Oncology’s annual meeting in Chicago, alongside pledges to advance it into phase 2 studies. | This week's sponsor is LabConnect. | | | SciOps Provides Solutions for Lost Samples, Missed Timelines and Scientific Personnel Needs
Managing outsourced studies can be challenging. Read how our team’s functional and strategic resourcing services allow you to focus on other core competencies. |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Presented By: Covance A solid RBM plan will not only help you comply with the ICH guidelines, but will help you mitigate risks which could ultimately delay your trials and increase costs. Download today! Presented by: Patheon, part of Thermo Fisher Scientific “Faster and better” has become the mantra for biopharmaceutical companies as they face intense pressure to get therapies to market faster. Quickly proving efficacy in first-in-human (FIH) trials is a make-or-break milestone for these cash-strapped companies whose hopes hinge upon one or two molecules. Read how CDMOs are responding to this pressure. Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Innovation, Collaboration and Entrepreneurship in Drug Discovery June 28, 2018 | Cambridge, UK FierceBiotech Executive Breakfast at BIO 2018 – CAR-T 2.0: Innovation Never Stands Still June 6, 2018 | Boston, MA CBI’s 14th Annual Medical Device Compliance Congress (MDCC) June 14-15, 2018 | Chicago, IL Sensors Expo & Conference Conference & Expo: June 26-28, 2018 | Pre-Conference Symposia: June 25, 2018 | San Jose, CA Drug Development Boot Camp® 2018 November 14-15, 2018 | Boston, MA | Register and start preparing Today! | 